{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:05:57Z","timestamp":1789589157317,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031826","name":"American Society of Gene and Cell Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000953","name":"Alliance for Cancer Gene Therapy Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["K00CA25375"],"award-info":[{"award-number":["K00CA25375"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA276512"],"award-info":[{"award-number":["R01CA276512"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["F31CA310236"],"award-info":[{"award-number":["F31CA310236"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1053\/j.gastro.2026.08.014","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:11:30Z","timestamp":1787836290000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Carbohydrate Antigen 19-9 Glycan Is a Viable Target for Chimeric Antigen Receptor T-Cell Therapy in Pancreatic and Other Solid Tumors"],"prefix":"10.1053","author":[{"given":"Feiyan","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin L.","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne C.","family":"McDevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dannielle D.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Avery D.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Z.","family":"Stanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2026.08.014_bib1","series-title":"Cancer facts & figures 2025","year":"2025"},{"key":"10.1053\/j.gastro.2026.08.014_bib2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1053\/j.gastro.2026.08.014_bib3","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","article-title":"The potential of CAR T cell therapy in pancreatic cancer","volume":"9","author":"Akce","year":"2018","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2026.08.014_bib4","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1053\/j.gastro.2012.07.017","article-title":"Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice","volume":"143","author":"Maliar","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.08.014_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.08.014_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.omto.2022.01.010","article-title":"The next wave of cellular immunotherapies in pancreatic cancer","volume":"24","author":"Yeo","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1053\/j.gastro.2026.08.014_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"10.1053\/j.gastro.2026.08.014_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.gastro.2026.08.014_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.gastro.2026.08.014_bib10","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1002\/pmic.201000827","article-title":"Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases","volume":"11","author":"Yue","year":"2011","journal-title":"Proteomics"},{"key":"10.1053\/j.gastro.2026.08.014_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jprot.2013.10.030","article-title":"Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays","volume":"96","author":"Rho","year":"2014","journal-title":"J Proteomics"},{"key":"10.1053\/j.gastro.2026.08.014_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/hyb.1983.2.219","article-title":"Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study","volume":"2","author":"Arends","year":"1983","journal-title":"Hybridoma"},{"key":"10.1053\/j.gastro.2026.08.014_bib13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/bjc.1991.90","article-title":"Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma","volume":"63","author":"Haglund","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1053\/j.gastro.2026.08.014_bib14","first-page":"54","article-title":"Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population","volume":"45","author":"Vestergaard","year":"1999","journal-title":"Clin Chem"},{"key":"10.1053\/j.gastro.2026.08.014_bib15","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/2211-5463.12278","article-title":"Distribution of Lewis and Secretor polymorphisms and corresponding CA19-9 antigen expression in a Chinese population","volume":"7","author":"Guo","year":"2017","journal-title":"FEBS Open Bio"},{"key":"10.1053\/j.gastro.2026.08.014_bib16","first-page":"148","article-title":"Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis)","volume":"10","author":"Bagaria","year":"2013","journal-title":"Cancer Biol Med"},{"key":"10.1053\/j.gastro.2026.08.014_bib17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3748\/wjg.v10.i3.427","article-title":"Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA","volume":"10","author":"Qin","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.014_bib18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aaw3145","article-title":"The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice","volume":"364","author":"Engle","year":"2019","journal-title":"Science"},{"key":"10.1053\/j.gastro.2026.08.014_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.21037\/jgo.2020.02.01","article-title":"Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer","volume":"11","author":"Gupta","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1053\/j.gastro.2026.08.014_bib20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"10.1053\/j.gastro.2026.08.014_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167099","article-title":"Biomolecular recognition of the glycan neoantigen CA19-9 by distinct antibodies","volume":"433","author":"Borenstein-Katz","year":"2021","journal-title":"J Mol Biol"},{"key":"10.1053\/j.gastro.2026.08.014_bib22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/1078-0432.CCR-10-2640","article-title":"Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity","volume":"17","author":"Sawada","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.gastro.2026.08.014_bib23","series-title":"Nucleic acids encoding human antibodies to sialyl-Lewis A","author":"Sawada","year":"2015"},{"key":"10.1053\/j.gastro.2026.08.014_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"10.1053\/j.gastro.2026.08.014_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Boj","year":"2015","journal-title":"Cell"},{"key":"10.1053\/j.gastro.2026.08.014_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-0716-0146-4_8","article-title":"Generation of chimeric antigen receptor T cells using gammaretroviral vectors","volume":"2086","author":"Mo","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1053\/j.gastro.2026.08.014_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/cancers14020344","article-title":"The diagnostic value of the CA19-9 and bilirubin ratio in patients with pancreatic cancer, distal bile duct cancer and benign periampullary diseases, a novel approach","volume":"14","author":"Boyd","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.gastro.2026.08.014_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117750","article-title":"The use of patient-derived xenografts and patient-derived organoids in the search for new therapeutic regimens for pancreatic carcinoma. A review","volume":"182","author":"Gayibov","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1053\/j.gastro.2026.08.014_bib29","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1158\/2159-8290.CD-24-1847","article-title":"Intrinsic properties of the lymph node render it immunologically susceptible to metastasis","volume":"15","author":"Kahn","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1053\/j.gastro.2026.08.014_bib30","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"10.1053\/j.gastro.2026.08.014_bib31","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.ymthe.2022.07.006","article-title":"Targeting glycans for CAR therapy: the advent of sweet CARs","volume":"30","author":"Raglow","year":"2022","journal-title":"Mol Ther"},{"key":"10.1053\/j.gastro.2026.08.014_bib32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/cancers14030645","article-title":"Targeting tumor glycans for cancer therapy: successes, limitations, and perspectives","volume":"14","author":"Berois","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.gastro.2026.08.014_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3748\/wjg.v3.i4.253","article-title":"Clinical significance of CA19-9 in diagnosis of digestive tract tumors","volume":"3","author":"Zhao","year":"1997","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.014_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf1426","article-title":"CD19 CAR antigen engagement mechanisms and affinity tuning","volume":"8","author":"He","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1053\/j.gastro.2026.08.014_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","article-title":"Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent","volume":"21","author":"Gomes-Silva","year":"2017","journal-title":"Cell Rep"},{"key":"10.1053\/j.gastro.2026.08.014_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.gastro.2026.08.014_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106329","article-title":"Locoregional delivery of CAR-T cells in the clinic","volume":"182","author":"Sagnella","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1053\/j.gastro.2026.08.014_bib38","first-page":"1001","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"NatMed"},{"key":"10.1053\/j.gastro.2026.08.014_bib39","first-page":"1320","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"NatMed"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508526071817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508526071817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:36:51Z","timestamp":1789587411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508526071817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"alternative-id":["S0016508526071817"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2026.08.014","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Carbohydrate Antigen 19-9 Glycan Is a Viable Target for Chimeric Antigen Receptor T-Cell Therapy in Pancreatic and Other Solid Tumors","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2026.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}